Replicating viruses as selective cancer therapeutics.
Replication-competent viruses are used as selective cancer therapeutics and the mechanisms leading to tumor-specific replication and antitumoral efficacy are now becoming apparent. The specific viruses in development include tumor-targeting herpes simplex viruses, autonomous parvoviruses, Newcastle disease viruses and adenovirus. Information is also available on antiviral immunology and viral defenses against host-mediated immunity. This approach has many potential attributes, in addition to potential hurdles that must be overcome.
Kirn
D H
DH
Director of Pre-clinical and Clinical Research, ONYX Pharmaceuticals, Richmond, CA 94806, USA.
McCormick
F
F
D000260:Adenoviruses, Human / Q000276:immunology / Q000502:physiology; D000818:Animals; D005822:Genetic Vectors / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009522:Newcastle disease virus / Q000276:immunology / Q000502:physiology; D017992:Parvovirus / Q000276:immunology / Q000502:physiology; D018139:Simplexvirus / Q000276:immunology / Q000502:physiology; D014764:Viral Proteins / Q000276:immunology; D018406:Virus Physiological Phenomena; D014779:Virus Replication
D014764:Viral Proteins